Trevena (NASDAQ:TRVN) Now Covered by Analysts at

Equities researchers at started coverage on shares of Trevena (NASDAQ:TRVNGet Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their target price on shares of Trevena from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 16th.

View Our Latest Analysis on Trevena

Trevena Stock Performance

Shares of NASDAQ TRVN opened at $0.40 on Friday. The company has a current ratio of 3.60, a quick ratio of 3.60 and a debt-to-equity ratio of 8.35. The stock has a market capitalization of $7.33 million, a PE ratio of -0.15 and a beta of 1.07. Trevena has a twelve month low of $0.30 and a twelve month high of $1.12. The stock has a fifty day simple moving average of $0.40 and a 200-day simple moving average of $0.54.

Trevena (NASDAQ:TRVNGet Free Report) last released its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million during the quarter. On average, equities analysts forecast that Trevena will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC bought a new stake in Trevena, Inc. (NASDAQ:TRVNFree Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned approximately 0.32% of Trevena as of its most recent SEC filing. Institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

See Also

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.